Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
作者： Jianxin Zhao , Rina Wu , Alfred Au , Abbey Marquez , Yibing Yu
DOI: 10.1038/MODPATHOL.3880582
关键词: Digoxigenin 、 Pathology 、 HercepTest 、 Polysomy 、 Chromosome 17 (human) 、 Chromogenic in situ hybridization 、 CISH 、 Hybridization probe 、 Molecular biology 、 Biology 、 In situ hybridization
摘要: Purpose: To compare the efficacy of chromogenic in situ hybridization (CISH™) with fluorescence (FISH) and immunohistochemistry (IHC) determination HER2 status human breast cancer. Materials Methods: gene amplification was determined on formalin-fixed paraffin-embedded (FFPE) sections 62 invasive cancers by FISH followed CISH using a digoxigenin (DIG)-labeled DNA probe generated Subtraction Probe Technology (SPT™), biotin-labeled chromosome 17 centromeric (chr.17cen) probe. The were heat treated enzyme digested. After hybridization, detected fluorescein (FITC)-anti-DIG for FISH, peroxidase-anti-FITC diaminobenzidine (DAB) CISH. chr.17cen peroxidase–streptavidin DAB. For application, copies or centromeres morphology cells easily visualized simultaneously 40 × objective under bright-field microscope hematoxylin-counterstained sections. IHC study overexpression performed adjacent panel three antibodies (TAB 250, CB11, A0485), staining scored according to criteria specified HercepTest. Results: typically as large DAB-stained clusters many dots nucleus. identified 19% tumors. Chromosome polysomy 31% demonstrated 250), 23% (CB11), 36% (A0485) Complete concordance between results TAB A0485 seen 100%, 97%, 94%, 84% cases, respectively. Conclusion: By permitting observation microscope, is an accurate, practical, economical approach screen cancers. It useful methodology confirming ambiguous results.
nature.com
researchgate.net 
sci-hub.se 参考文章(38)
J A Fletcher, J S Ross, HER-2/neu (c-erb-B2) gene and protein in breast cancer. American Journal of Clinical Pathology. ,vol. 112, ,(1999)
Godolphin W, Pauletti G, Press Mf, Slamon Dj, Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. ,vol. 13, pp. 63- 72 ,(1996)
M F Press, L Bernstein, P A Thomas, L F Meisner, J Y Zhou, Y Ma, G Hung, R A Robinson, C Harris, A El-Naggar, D J Slamon, R N Phillips, J S Ross, S R Wolman, K J Flom, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology. ,vol. 15, pp. 2894- 2904 ,(1997) , 10.1200/JCO.1997.15.8.2894
R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, T.M. Grogan, Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message Journal of Clinical Oncology. ,vol. 19, pp. 2714- 2721 ,(2001) , 10.1200/JCO.2001.19.10.2714
Diane M. Maia, Immunohistochemical Assays for HER2 Overexpression Journal of Clinical Oncology. ,vol. 17, pp. 1644- 1644 ,(1999) , 10.1200/JCO.1999.17.5.1644G
Inny Busmanis, Frank Feleppa, Amanda Jones, Katherine M. McGrath, Richard Reed, John Collins, Ian Russell, C. Glenn Begley, Analysis of cerbB2 expression using a panel of 6 commercially available antibodies Pathology. ,vol. 26, pp. 261- 267 ,(1994) , 10.1080/00313029400169611
O. P. Kallioniemi, A. Kallioniemi, W. Kurisu, A. Thor, L. C. Chen, H. S. Smith, F. M. Waldman, D. Pinkel, J. W. Gray, ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 89, pp. 5321- 5325 ,(1992) , 10.1073/PNAS.89.12.5321
Ren L Ridolfi, Mehdi R Jamehdor, Janet M Arber, HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Modern Pathology. ,vol. 13, pp. 866- 873 ,(2000) , 10.1038/MODPATHOL.3880154
Hiroyuki Kumamoto, Hironobu Sasano, Takahiro Taniguchi, Takashi Suzuki, Takuya Moriya, Ryo Ichinohasama, Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (HerceptinR) therapy Pathology International. ,vol. 51, pp. 579- 584 ,(2001) , 10.1046/J.1440-1827.2001.01255.X
E W Kay, C J Walsh, M Cassidy, B Curran, M Leader, C-erbB-2 immunostaining: problems with interpretation. Journal of Clinical Pathology. ,vol. 47, pp. 816- 822 ,(1994) , 10.1136/JCP.47.9.816